INMUNE BIO INC. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
INMUNE BIO INC. (INMB) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $598.63 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2021-03-04
- INMUNE BIO INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2020 was $598.63K, a 25.59% decline from fiscal 2019.
- INMUNE BIO INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2019 was $804.46K, a 48.00% decline from fiscal 2018.
- INMUNE BIO INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2018 was $1.55M, a 19849.99% increase from fiscal 2017.
- INMUNE BIO INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2017 was $7.75K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2020-12-31 | $598.63K 10-K · filed 2021-03-04 |
| 2019-12-31 | $804.46K 10-K · filed 2021-03-04 |
| 2018-12-31 | $1.55M 10-K · filed 2020-03-11 |
| 2017-12-31 | $7.75K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |